Reyon Pharmaceutical Co Ltd
REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough … Read more
Reyon Pharmaceutical Co Ltd (102460) - Net Assets
Latest net assets as of September 2025: ₩233.12 Billion KRW
Based on the latest financial reports, Reyon Pharmaceutical Co Ltd (102460) has net assets worth ₩233.12 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩473.11 Billion) and total liabilities (₩239.99 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩233.12 Billion |
| % of Total Assets | 49.27% |
| Annual Growth Rate | 11.69% |
| 5-Year Change | 8.63% |
| 10-Year Change | 97.81% |
| Growth Volatility | 23.02 |
Reyon Pharmaceutical Co Ltd - Net Assets Trend (2008–2024)
This chart illustrates how Reyon Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Reyon Pharmaceutical Co Ltd (2008–2024)
The table below shows the annual net assets of Reyon Pharmaceutical Co Ltd from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩249.94 Billion | +0.53% |
| 2023-12-31 | ₩248.62 Billion | +0.35% |
| 2022-12-31 | ₩247.77 Billion | +1.03% |
| 2021-12-31 | ₩245.24 Billion | +6.58% |
| 2020-12-31 | ₩230.09 Billion | +3.51% |
| 2019-12-31 | ₩222.29 Billion | -1.38% |
| 2018-12-31 | ₩225.39 Billion | +2.61% |
| 2017-12-31 | ₩219.66 Billion | +22.65% |
| 2016-12-31 | ₩179.10 Billion | +41.74% |
| 2012-12-31 | ₩126.36 Billion | +19.80% |
| 2011-12-31 | ₩105.47 Billion | +76.49% |
| 2009-12-31 | ₩59.76 Billion | +40.18% |
| 2008-12-31 | ₩42.63 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Reyon Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 490.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩207.40 Billion | 82.98% |
| Other Components | ₩42.54 Billion | 17.02% |
| Total Equity | ₩249.94 Billion | 100.00% |
Reyon Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Reyon Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shagrir Group Vehicle Services Ltd
PINK:SRRPF
|
$20.75 Million |
|
Rayence Co. Ltd
KQ:228850
|
$20.76 Million |
|
Bizim Toptan Satis Magazalari AS
IS:BIZIM
|
$20.76 Million |
|
TAO Synergies Inc.
NASDAQ:TAOX
|
$20.76 Million |
|
N. B. I. Industrial Finance Company Limited
NSE:NBIFIN
|
$20.74 Million |
|
Hyungkuk F&B Co Ltd
KQ:189980
|
$20.74 Million |
|
Argo Pantes Tbk
JK:ARGO
|
$20.74 Million |
|
Budapesti Ãrtéktozsde Nyilvánosan Muködo Részvénytársaság
BUD:BET
|
$20.73 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Reyon Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 248,624,544,580 to 249,941,078,890, a change of 1,316,534,310 (0.5%).
- Net income of 4,151,240,200 contributed positively to equity growth.
- Dividend payments of 2,751,148,650 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩4.15 Billion | +1.66% |
| Dividends Paid | ₩2.75 Billion | -1.1% |
| Other Changes | ₩-83.56 Million | -0.03% |
| Total Change | ₩- | 0.53% |
Book Value vs Market Value Analysis
This analysis compares Reyon Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.75x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩12842.80 | ₩10270.00 | x |
| 2018-12-31 | ₩13258.86 | ₩10270.00 | x |
| 2019-12-31 | ₩13061.74 | ₩10270.00 | x |
| 2020-12-31 | ₩13284.40 | ₩10270.00 | x |
| 2021-12-31 | ₩13814.03 | ₩10270.00 | x |
| 2022-12-31 | ₩13956.44 | ₩10270.00 | x |
| 2023-12-31 | ₩13555.68 | ₩10270.00 | x |
| 2024-12-31 | ₩13627.46 | ₩10270.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Reyon Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.66%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.80%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 2.00x
- Recent ROE (1.66%) is below the historical average (7.97%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 18.65% | 10.75% | 1.12x | 1.55x | ₩3.64 Billion |
| 2009 | 27.53% | 17.11% | 1.16x | 1.38x | ₩10.37 Billion |
| 2011 | 18.75% | 15.91% | 0.93x | 1.27x | ₩9.23 Billion |
| 2012 | 13.45% | 14.86% | 0.73x | 1.24x | ₩4.36 Billion |
| 2016 | 5.98% | 8.78% | 0.58x | 1.17x | ₩-7.21 Billion |
| 2017 | 5.87% | 10.21% | 0.43x | 1.32x | ₩-9.08 Billion |
| 2018 | 0.60% | 1.09% | 0.41x | 1.36x | ₩-21.01 Billion |
| 2019 | 2.70% | 4.52% | 0.48x | 1.25x | ₩-16.08 Billion |
| 2020 | 1.67% | 2.96% | 0.41x | 1.38x | ₩-19.16 Billion |
| 2021 | 2.26% | 3.88% | 0.30x | 1.95x | ₩-18.99 Billion |
| 2022 | 3.00% | 4.83% | 0.32x | 1.96x | ₩-17.34 Billion |
| 2023 | 1.44% | 2.37% | 0.30x | 2.01x | ₩-21.28 Billion |
| 2024 | 1.66% | 2.80% | 0.30x | 2.00x | ₩-20.84 Billion |
Industry Comparison
This section compares Reyon Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $185,563,423,740
- Average return on equity (ROE) among peers: 1.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Reyon Pharmaceutical Co Ltd (102460) | ₩233.12 Billion | 18.65% | 1.03x | $20.74 Million |
| Dongwha Pharm.Co.Ltd (000020) | $229.73 Billion | 2.15% | 0.36x | $75.32 Million |
| Yuhan Corp. (000100) | $323.58 Billion | 10.19% | 0.72x | $4.21 Billion |
| Yuyu Pharma Inc (000227) | $128.69 Billion | -1.72% | 0.50x | $26.44 Million |
| Ildong Holdings Co Ltd (000230) | $66.98 Billion | 10.88% | 1.80x | $49.55 Million |
| Samil Pharm (000520) | $62.87 Billion | 0.00% | 0.77x | $110.58 Million |
| Donga Socio Holdings (000640) | $328.69 Billion | 10.58% | 1.17x | $206.35 Million |
| Jw Pharmac (001060) | $223.83 Billion | 0.28% | 1.65x | $278.34 Million |
| JW Pharmaceutical Corp (001067) | $265.44 Billion | 13.94% | 1.43x | $489.75 Million |
| Samsung Pharm (001360) | $77.58 Billion | -31.98% | 0.20x | $65.82 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $148.25 Billion | 1.71% | 0.47x | $27.39 Million |